(2016). “Loss of IFN-gamma Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy.” Cell 167(2): 397-404 e399 in vivo CTLA-4 neutralization Bartkowiak, T., et al. (2015). “Unique potentia...
View Human/Mouse CTLA-4 Antibody (MAB386) validated in Human and Mouse. Additional non-catalog clones available.
Here, we show that CTLA-4 is expressed by innate lymphoid cells and that its expression is regulated by ILC subset-specific cytokine cues in a microbiota-dependent manner. Genetic deletion or antibody blockade of CTLA-4 in multiple in vivo models of colitis demonstrates that this pathway plays ...
in vivo CTLA-4 neutralization Bartkowiak, T., et al. (2015). “Unique potential of 4-1BB agonist antibody to promote durable regression of HPV+ tumors when combined with an E6/E7 peptide vaccine.” Proc Natl Acad Sci U S A 112(38): E5290-5299. in vivo CTLA-4 neutralization Sprang...
is provided, wherein the method comprises: (a) an IL-2Rβ activating amount of a long acting IL-2Rβ selective agonist; 2.) administering to a cancer patient a CTLA-4 pathway inhibitory amount of an anti-CTLA-4 antibody or a PD-1 pathway inhibitory amount of an anti-PD-1 antibody....
Cadonilimab, also referred to as AK104, is a humanized bsAb targeting PD-1 and CTLA-4. Functioning as a symmetric tetravalent bifunctional antibody, it binds simultaneously with high affinity to PD-1 and CTLA-4 expressed on tumor-infiltrating lymphocytes (TILs), achieving a co-targeting effect...
Cytokine induced memory-like natural killer (CIML NK) cells combined with an IL-15 super-agonist (N-803) are a novel modality to treat relapsed/refractory head and neck cancer. We report data from a phase I trial of haploidentical CIML NK cells combined
Inhibition of T cell activation and autoimmune diabetes using a B cell surface-linked CTLA-4 agonist. J Clin Invest, 116 (2006), pp. 2252-2261 CrossrefView in ScopusGoogle Scholar 47 RJ Greenwald, MA Oosterwegel, D van der Woude, et al. CTLA-4 regulates cell cycle progression during a...
N. et al. Publisher correction: antibody and TLR7 agonist delay viral rebound in SHIV-infected monkeys. Nature 564, E8 (2018). CAS PubMed Google Scholar Weiss, L. et al. Human immunodeficiency virus-driven expansion of CD4+CD25+ regulatory T cells, which suppress HIV-specific CD4 T-cell...
Provided herein are novel ABPs with binding specificity for CTLA-4 and methods of using such ABPs. The CTLA-4 is a human CTLA-4 (SEQ ID: 7001) or a fragment of the human CTLA-4. The ABP can comprise an antibody. In some embodiments, the antibody is a monoclonal antibody. In some...